We are joined by Petra Langerbeins at the EHA annual meeting in Amsterdam to discuss her presentation on ibrutinib versus placebo in patients with asymptomatic, treatment-naive early-stage chronic lymphocytic leukaemia (CLL): primary endpoint results of the phase III double-blind randomised CLL12 trial.
1. What is the current treatment paradigm for patients with asymptomatic early-stage chronic lymphocytic leukaemia (CLL)? (0:05)
2. What are the limitations of available treatment options for people with asymptomatic high-risk CLL? (0:30)
3. Could you tell us a little about the findings of the phase III study of ibrutinib in this treatment setting? (1:06)
4. Which patients are most likely to respond to ibrutinib and in which is it contraindicated? (2:50)
5. What is the safety profile of ibrutinib and how can adverse events be managed? (3:55)
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Leukaemia
Andreas Hochhaus, ASH 2020 – The ASCEMBL Study and Asciminib in CML
touchONCOLOGY meets with Prof. Andreas Hochhaus to discuss the clinical development of asciminib and its potential as a therapy for chronic myeloid leukaemia. The abstract ‘Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic […]
Othman Al-Sawaf, ASH 2020 – Venetoclax-obinutuzumab and the CLL14 Trial
Dr Othman Al-Sawaf joins touchONCOLOGY to discuss the CLL14 trial and the impact of venetoclax-obinutuzumab treatment on clonal growth and the potential of its use in chronic lymphocytic leukaemia. The abstract ‘Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial’ (Abstract number 127) was presented at the 62nd American Society […]
Massimo Breccia, ASH 2019: Discontinuing Tyrosine-kinase Inhibitors in patients with Chronic Myeloid Leukemia
At the 61st ASH Annual Meeting & Exposition, Massimo Breccia, Sapienza University of Rome, discusses discontinuing tyrosine-kinase inhibitors (TKIs) in patients with chronic myeloid leukemia. Questions 1. What is the rationale for discontinuing tyrosine-kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML)? (0:05) 2. Following discontinuation of TKIs in patients with CML, when are […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!